Targeting E3 Ubiquitin Ligases in Post-Traumatic Osteoarthritis: Therapeutic Opportunities and Pharmacological Perspectives
Pharmaceutics · 29.05.2026 · 18 (6) · 673
DOI: 10.3390/pharmaceutics18060673 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.05.2026. Verfasst von Yinqiu Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, School of Medicine, Yangzhou University, Yangzhou 225001, China. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Center for Collaborative Innovation in Geographical Information Resource Development and Application, Jiangsu Provincial Academy of Traditional Chinese Medicine, Jiangsu Education Department.
Abstract (Originalsprache)
Post-traumatic osteoarthritis (PTOA) is a rapidly progressing joint disorder initiated by acute injury, characterized by persistent inflammation, chondrocyte dysfunction, and extracellular matrix (ECM) degradation. Despite its clinical burden, effective disease-modifying therapies are lacking. Increasing evidence suggests that the ubiquitin–proteasome system, particularly E3 ubiquitin ligases, plays a pivotal role in regulating key pathogenic pathways involved in PTOA and represents a potentially druggable regulatory axis. In this review, we provide a comprehensive overview of the emerging roles of E3 ubiquitin ligases in PTOA, highlighting their involvement in inflammatory signaling, chondrocyte fate regulation, and cartilage matrix remodeling. We further integrate the current findings into a unified framework, in which E3 ligases act as central regulatory nodes linking injury-induced molecular responses to chronic joint degeneration. Importantly, we emphasize the pharmacological and translational potential of targeting E3 ubiquitin ligases as a novel therapeutic strategy. Recent advances in small-molecule modulators, gene-based interventions, and proteolysis-targeting chimeras (PROTACs) highlight the druggability of this regulatory system and provide new opportunities for disease-modifying treatment in PTOA. We also discuss the current challenges, including context-dependent effects, limited PTOA-specific validation, and delivery barriers. Overall, this review provides a comprehensive and therapeutically oriented perspective on E3 ubiquitin ligases in PTOA and highlights their potential as promising targets for pharmacological intervention and disease-modifying therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Translational Medicine, School of Medicine, Yangzhou University, Yangzhou 225001, China.
- The Key Laboratory of the Jiangsu Higher Education Institutions for Nucleic Acid & Cell Fate Regulation, Yangzhou University, Yangzhou 225001, China.
- First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China.
ORCID-Profile: Yinqiu Wu, Yanyan Xue, Hua Dai
Förderung
- Jiangsu Center for Collaborative Innovation in Geographical Information Resource Development and Application
- Jiangsu Provincial Academy of Traditional Chinese Medicine
- Jiangsu Education Department
- Graduate Student Research and Practice and Innovation Program of Jiangsu Province
- Jiangsu Province Traditional Chinese Medicine Science and Technology Development Plan Project
- Major Project of Natural Science Research in Higher Educational Institutions of Jiangsu Province
Zitieren
APA
Wu, Y., Zhang, J., Zhang, L., Li, W., Xue, Y., Zhang, S., & Dai, H. (2026). Targeting E3 Ubiquitin Ligases in Post-Traumatic Osteoarthritis: Therapeutic Opportunities and Pharmacological Perspectives. Pharmaceutics, 18(6), 673. https://doi.org/10.3390/pharmaceutics18060673
Vancouver
Wu Y, Zhang J, Zhang L, Li W, Xue Y, Zhang S, et al. Targeting E3 Ubiquitin Ligases in Post-Traumatic Osteoarthritis: Therapeutic Opportunities and Pharmacological Perspectives. Pharmaceutics. 2026;18(6):673. doi:10.3390/pharmaceutics18060673
BibTeX
@article{Wu2026,
author = {Wu, Yinqiu and Zhang, Jun and Zhang, Liyong and Li, Wei and Xue, Yanyan and Zhang, Shengzhe and Dai, Hua},
title = {Targeting E3 Ubiquitin Ligases in Post-Traumatic Osteoarthritis: Therapeutic Opportunities and Pharmacological Perspectives},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {6},
pages = {673},
doi = {10.3390/pharmaceutics18060673}
}
EUVIMED